Since its approval in 1997 by the Food and Drug Administration (FDA), anti-CD20 therapy has revolutionized the treatment of B-cell hematological malignancies, namely for indolent and aggressive subtypes of B-cell non-Hodgkin (NHL) and chronic lymphocytic leukemia (CLL), reducing mortality and improving the overall prognosis of patients with acceptable toxicity3,4. Here, MS4A1 is linked to B-cell chronic lymphocytic leukemia.